md-medicaldata

Authors

Marko Dević^1,2, Milica Pisarić^1,2, Tamara Zelenović^1,2, Dušan Zbućnović², Bojan Stanimirov<sup>3

1</sup>Medicinski fakultet, Univerzitet u Novom Sadu, Novi Sad, Srbija
²Klinika za otorinolaringologiju i hirurgiju glave i vrata, Univerzitetski klinički centar Vojvodine, Novi Sad, Srbija
³Katedra za biohemiju, Medicinski fakultet, Univerzitet u Novom Sadu, Novi Sad, Srbija

 

UDK: 612.6.05:575

The paper was received / Rad primljen 03.04.2025.

Accepted / Rad prihvaćen: 21.04.2025.

 

Correspondence to:

Marko Dević
Univerzitet u Novom Sadu, Medicinski fakultet;
Klinika za otorinolaringologiju i hirurgiju glave i vrata,
Univerzitetski klinički centar Vojvodine, Novi Sad, Srbija
Hajduk Veljkova 3, 21000, Novi Sad
ORCID iD: 0009-0007-8565-0254
e-mail: marko.devic@mf.uns.ac.rs

 

 

Sažetak

 

 

Editovanje genoma je koncept koji se razvija već decenijama, a smatra se jednim od najvažnijih dostignuća savremene nauke, sa potencijalom da unapredi personalizovanu medicinu. Među različitim metodama, CRISPR-Cas tehnologija se ističe zbog svoje efikasnosti i preciznosti, što je čini posebno značajnom za primenu u biomedicini. Cilj ovog rada bio je da se ukratko objasne osnove editovanja genoma, s posebnim osvrtom na CRISPR-Cas sistem. Ova tehnologija pokazuje veliki potencijal za primenu u biomedicini, posebno u terapiji genetskih oboljenja. Njene prednosti, poput jednostavnosti korišćenja i visokog stepena specifičnosti, čine je ključnim alatom u savremenim istraživanjima. Ipak, uprkos obećavajućim rezultatima, još uvek postoje brojni izazovi koji sprečavaju njenu širu primenu. Pored tehničkih ograničenja, otvorena su i etička i pravna pitanja koja zahtevaju dodatna istraživanja i regulativne okvire.

 

Ključne reči:

CRISPR, editovanje genoma, genska terapija, personalizovana medicina

 

 

 

Abstract

 

Genome editing is a concept that has been developing for decades and is considered one of the most significant achievements of modern science, with the potential to advance personalized medicine. Among various methods, the CRISPR-Cas technology stands out due to its efficiency and precision, making it particularly important for biomedical applications. The aim of this paper was to briefly explain the fundamentals of genome editing, with a special focus on the CRISPR-Cas system. This technology shows great potential for biomedical applications, especially in the treatment of genetic disorders. Its advantages, such as ease of use and high specificity, make it a key tool in contemporary research. However, despite promising results, numerous challenges still hinder its widespread application. In addition to technical limitations, ethical and legal issues remain open, requiring further research and regulatory frameworks.

 

Key words:

CRISPR, genome editing, genetic therapy, personalized medicine

 

 

 

 

References:

1. Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective. Clin Transl Sci. 2018;11(1):11-20.
2. Matuszewska KE, Bukowska-Olech E, Piechota M, Staniek-Łacna K, Drews K, Więckowska B, et al. From chromosomal aberrations to mutations in individual genes - the significance of genetic studies of chorions after miscarriage in the search for causes of miscarriages. J Matern Fetal Neonatal Med. 2024;37(1):2364249. doi:10.1080/14767058.2024.2364249
3. Roth TL, Marson A. Genetic Disease and Therapy. Annu Rev Pathol. 2021;16:145–66.
4. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229–36.
5. Zhang Y, Iaffaldano B, Qi Y. CRISPR ribonucleoprotein-mediated genetic engineering in plants. Plant Commun. 2021;2(2):100168. doi: 10.1016/j.xplc.2021.100168
6. Liao H, Wu J, VanDusen NJ, Li Y, Zheng Y. CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol Ther Nucleic Acids. 2024;35(4):102344. doi: 10.1016/j.omtn.2024.102344
7. Huang S, Yan Y, Su F, Huang X, Xia D, Jiang X, et al. Research progress in gene editing technology. Front Biosci. 2021;26(10):916–27.
8. Fiegl H, Schnaiter S, Reimer DU, Leitner K, Nardelli P, Tsibulak I, et al. BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer. Clin Epigenetics. 2024;16(1):171. doi: 10.1186/s13148-024-01781-0
9. Zhao B, Rothenberg E, Ramsden DA, Lieber MR. The molecular basis and disease relevance of non-homologous DNA end joining. Nat Rev Mol Cell Biol. 2020;21(12):765-781.
10. Yang N, Wang R, Zhao Y. Revolutionize Genetic Studies and Crop Improvement with High-Throughput and Genome-Scale CRISPR/Cas9 Gene Editing Technology. Mol Plant. 2017;10(9):1141–3.
11. Li C, Brant E, Budak H, Zhang B. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. J Zhejiang Univ Sci B. 2021;22(4):253–84.
12. Tröder SE, Zevnik B. History of genome editing: From meganucleases to CRISPR. Lab Anim. 2022;56(1):60-68. doi: 10.1177/0023677221994613
13. Khalil AM. The genome editing revolution: review. J Genet Eng Biotechnol. 2020;18(1):68. doi: 10.1186/s43141-020-00078-y.
14. Tamura R, Toda M. Historic Overview of Genetic Engineering Technologies for Human Gene Therapy. Neurol Med Chir. 2020;60(10):483–91.
15. Ho BX, Loh SJH, Chan WK, Soh BS. In Vivo Genome Editing as a Therapeutic Approach. Int J Mol Sci. 2018;19(9):2721. doi: 10.3390/ijms19092721.
16. Katayama S, Watanabe M, Kato Y, Nomura W, Yamamoto T. Engineering of Zinc Finger Nucleases Through Structural Modeling Improves Genome Editing Efficiency in Cells. Adv Sci. 2024;11(23):e2310255. doi: 10.1002/advs.202310255
17. Zhang HX, Zhang Y, Yin H. Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9. Mol Ther. 2019;27(4):735–46.
18. Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M. Various Aspects of a Gene Editing System-CRISPR-Cas9. Int J Mol Sci. 2020;21(24):1–20.
19. Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. J Bacteriol. 2018;200(7):e00580-17. doi: 10.1128/JB.00580-17.
20. Zhang D, Zhang Z, Unver T, Zhang B. CRISPR/Cas: A powerful tool for gene function study and crop improvement. J Adv Res. 2020;29:207–21.
21. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. doi: 10.1126/science.1258096.
22. Palermo G. Structure and Dynamics of the CRISPR-Cas9 Catalytic Complex. J Chem Inf Model. 2019;59(5):2394-2406. doi: 10.1021/acs.jcim.8b00988
23. Cui Y, Xu J, Cheng M, Liao X, Peng S. Review of CRISPR/Cas9 sgRNA Design Tools. Interdiscip Sci. 2018;10(2):455–65.
24. De Masi C, Spitalieri P, Murdocca M, Novelli G, Sangiuolo F. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics. 2020;14(1):25. doi: 10.1186/s40246-020-00276-2.
25. Yang H, Ren S, Yu S, Pan H, Li T, Ge S, et al. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. Int J Mol Sci. 2020;21(18):6461. doi: 10.3390/ijms21186461
26. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. Cells. 2020;9(7):1608. doi: 10.3390/cells9071608.
27. Glavaski M, Stankov K. Epigenetics in disease etiopathogenesis. Genetika. 2019;51(3):975–94.
28. Khosravi S, Hinrichs R, Rönspies M, Haghi R, Puchta H, Houben A. Epigenetic state and gene expression remain stable after CRISPR/Cas-mediated chromosomal inversions. New Phytol. 2025 Jan 29. doi: 10.1111/nph.20403. Epub ahead of print. PMID: 39878102.
29. Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Mol Ther. 2021;29(2):571-86.
30. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–9.
31. Kantor A, McClements ME, Maclaren RE. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int J Mol Sci. 2020;21(17):1–22.
32. Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25(2):229–33.
33. Foss D V., Hochstrasser ML, Wilson RC. Clinical applications of CRISPR-based genome editing and diagnostics. Transfusion. 2019;59(4):1389–99.
34. Memi F, Ntokou A, Papangeli I. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations. Semin Perinatol. 2018;42(8):487–500.
35. Savić N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15–21.
36. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21.
37. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380-9.
38. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013;110(39):15644–9.
39. Hirano H, Gootenberg JS, Horii T, Abudayyeh OO, Kimura M, Hsu PD, et al. Structure and Engineering of Francisella novicida Cas9. Cell. 2016;164(5):950–61.
40. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234-57.
41. Wang HX, Li M, Lee CM, Chakraborty S, Kim HW, Bao G, et al. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. Chem Rev. 2017;117(15):9874–906.
42. Yip BH. Recent Advances in CRISPR/Cas9 Delivery Strategies. Biomolecules. 2020;10(6):839. doi: 10.3390/biom10060839.
43. Furrow B. The CRISPR-Cas9 Tool of Gene Editing: Cheaper, Faster, Riskier?. Ann Health L. 2017;26(2):32-51.
44. Aikyo T, Kogetsu A, Kato K. Stakeholder Involvement in the Governance of Human Genome Editing in Japan. Asian Bioeth Rev. 2023;1–25. https://doi.org/10.1007/s41649-023-00251-8.
45. Noohi F, Ravitsky V, Knoppers BM, Joly Y. Mitochondrial Replacement Therapy: In Whose Interests?. J Law Med Ethics. 2022;50(3):597-602.
46. Polcz S, Lewis A. CRISPR-Cas9 and the non-germline non-controversy. J Law Biosci. 2016;3(2):413–25.
47. Sovilj R, Stojković Zlatanović S. Pravne, socijalne i etičke implikacije editovanja humanog genoma primenom tehnologije CRISPR/Cas9. Anali Pravnog fakulteta u Beogradu. 2021;69(3):625–45.
48. Stankov K, Draskovic D, Mikov M. Ethical and legal aspects of oncogenomics. J BUON. 2012;17(2):383–8.
    

PDF: 06-Dević M. et al. MD-Medical Data 2025;17(2) 117-122.pdf